Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8...Show More
peer of
Metrics
marketSTOCKS
msh_idCOM:REGULUSRX
localeus
websitehttps://www.regulusrx.com/
ipo_date2012-10-09
primary_stock_msh_idNASDAQ:RGLS
source_ref290e50e4-60b5-4183-9562-ecbb2810b930
company_size51
products_or_servicesMicroRNA-based therapeutics for kidney diseases.